Morgan Stanley lowered the firm’s price target on Bayer to EUR 35 from EUR 45 and keeps an Equal Weight rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- Burning Rock Biotech enters collaboration with Bayer to develop cancer medicine
- Bayer initiated with a Neutral at Goldman Sachs
- Bayer: Secondary endpoints met in elinzanetant study for menopause symptoms
- Bayer sees FY24 core EPS EUR 5.10- EUR 5.50
- Bayer reports Q1 core EPS EUR 2.82 vs. EUR 2.95 last year
Questions or Comments about the article? Write to editor@tipranks.com